Molecular targets for the treatment of multiple myeloma

Current Cancer Drug Targets

Volumn 12, Issue 7, 2012, Pages 757-767

  Rossi, Marco ^a   Di Martino, Maria Teresa ^a   Morelli, Eugenio ^a   Leotta, Marzia ^a   Rizzo, Antonietta ^b   Grimaldi, Anna ^b   Misso, Gabriella ^b   Tassone, Pierfrancesco ^a   Caraglia, Michele ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bone disease; Epigenetic therapy; Molecular pathway; Monoclonal antibodies; Multiple myeloma; Target therapy

Indexed keywords

AURORA KINASE INHIBITOR; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR ANTIBODY; BELINOSTAT; BORTEZOMIB; DENOSUMAB; DEXAMETHASONE; DNA; ENZASTAURIN; EVEROLIMUS; HISTONE; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PANOBINOSTAT; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN ANTIBODY; PROTEIN KINASE B; PROTEIN KINASE C; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; OSSIFICATION; OSTEOLYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION;

EID: 84866418812     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912802429300     Document Type: Article

References (77)

1. Caers, J.; Vande broek, I.; De Raeve, H.; Michaux, L.; Trullemans, F.; Schots, R.; Van Camp, B.; Vanderkerken, K. Multiple myeloma--an update on diagnosis and treatment. Eur. J. Haematol. 2008, 81, 329-343.
2. Younes, H.; Leleu, X.; Hatjiharissi, E.; Moreau, A. S.; Hideshima, T.; Richardson, P.; Anderson, K. C.; Ghobrial, I. M. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin. Cancer Res. 2007, 13, 3771-3775.
3. Teachey, D. T.; Grupp, S. A.; Brown, V. I. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br. J. Haematol. 2009, 145, 569-580.
4. Peterson, T. R.; Laplante, M.; Thoreen, C. C.; Sancak, Y.; Kang, S. A.; Kuehl, W. M.; Gray, N. S.; Sabatini, D. M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009, 137, 873-886.
5. van Zaanen, H. C.; Lokhorst, H. M.; Aarden, L. A.; Rensink, H. J.; Warnaar, S. O.; van der Lelie, J.; van Oers, M. H. Chimaeric antiinterleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 1998, 102, 783-790.
6. Fulciniti, M.; Hideshima, T.; Vermot-Desroches, C.; Pozzi, S.; Nanjappa, P.; Shen, Z.; Patel, N.; Smith, E. S.; Wang, W.; Prabhala, R.; Tai, Y. T.; Tassone, P.; Anderson, K. C.; Munshi, N. C. A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma. Clin. Cancer Res. 2009, 15, 7144-7152.
7. Hunsucker, S. A.; Magarotto, V; Kuhn, D. J.; Kornblau, S. M.; Wang, M.; Weber, D. M.; Thomas, S. K.; Shah, J. J.; Voorhees, P. M.; Xie, H.; Cornfeld, M.; Nemeth, J. A.; Orlowski, R. Z. Blockade of interleukin -6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br. J. Haematol. 2011, 152, 579-592.
8. Voorhees, P. M.; Chen, Q.; Kuhn, D. J.; Small, G. W.; Hunsucker, S. A.; Zaki, M. H.; Nemeth, J. A.; Orlowski, R. Z. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Br. J. Haematol. 2009, 145, 481-490.
9. Fizaki, K.; De Bono, J. S.; Flechon, A.; Heidenreich, A.; Voog, E.; Davis, N. B.; Qi, M.; Bandekar, R.; Vermeulen, J. T.; Cornfeld, M.; Hudes, G. R. Randomised phase II study of siltuximab (CNTO328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone alone in metastatic castration resistant prostate cancer. Eur. J. Cancer 2012, 48, 85-93.
10. Tassone, P.; Neri, P.; Burger, R.; Savino, R.; Shammas, M.; Catley, L.; Podar, K.; Chauhan, D.; Masciari, S.; Gozzini, A.; Tagliaferri, P.; Venuta, S.; Munshi, N. C.; Anderson, K. C. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin. Cancer Res. 2005, 11, 4251-4258.
11. Tassone, P.; Galea, E.; Forciniti, S.; Tagliaferri, P.; Venuta, S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int. J. Oncol. 2002, 21 (4), 867-873.
12. Sprynski, A. C.; Hose, D.; Caillot, L.; Réme, T.; Shaughnessy, J. D. Jr.; Barlogie, B.; Seckinger, A.; Moreaux, J.; Hundemer, M.; Jourdan, M.; Meissner, T.; Jauch, A.; Mahtouk, K.; Kassambara, A.; Bertsch, U.; Rossi, J. F.; Goldschmidt, H.; Klein, B. The role of IGF-1 as major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009, 113, 4614-4626.
13. Glassford, J.; Rabin, N.; Lam, E. W.; Yong, K. L. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells. Br. J. Haematol. 2007, 139, 243-254.
14. Baumann, P.; Hagemeier, H.; Mandl-Weber, S.; Franke, D.; Schmidmaier, R. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs 2009, 20, 259-266.
15. Maiso, P.; Ocio, E. M.; Garayoa, M.; Montero, J. C.; Hofmann, F.; García-Echeverría, C.; Zimmermann, J.; Pandiella, A.; San Miguel J. F. The insulin-like growth factor-I receptor inhibitor NVPAEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br. J. Haematol. 2008, 141, 470-482.
16. Cohen, B. D.; Baker, D. A.; Soderstrom, C.; Tkalcevic, G.; Rossi, A. M.; Miller, P. E.; Tengowski, M. W.; Wang, F.; Gualberto, A.; Beebe, J. S.; Moyer, J. D. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulinlike growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 2005, 11, 2063-2073.
17. Descamps, G.; Gomez-Bougie, P.; Venot, C.; Moreau, P.; Bataille, R.; Amiot, M. A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45. Br. J. Cancer 2009, 100(2), 366-369.
18. Lacy, M. Q.; Alsina, M.; Fonseca, R.; Paccagnella, M. L.; Melvin, C. L.; Yin, D.; Sharma, A.; Enriquez-Sarano, M.; Pollak, M.; Jagannath, S.; Richardson, P.; Gualberto, A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J. Clin. Oncol. 2008, 26, 3196-3203.
19. Moreau, P.; Cavallo, F.; Leleu, X.; Hulin, C.; Amiot, M.; Descamps, G.; Facon, T.; Boccadoro, M.; Mignard, D.; Harousseau J. L. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 2011, 25, 872-874.
20. Podar, K.; Tai, Y. T.; Davies, F. E.; Lentzsch, S.; Sattler, M.; Hideshima, T.; Lin, B. K.; Gupta, D.; Shima, Y.; Chauhan, D.; Mitsiades, C.; Raje, N.; Richardson, P.; Anderson, K. C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98, 428-435.
21. Podar, K.; Raab, M. S.; Zhang J.; McMillin, D.; Breitkreutz, I.; Tai, Y. T.; Lin, B. K.; Munshi, N.; Hideshima, T.; Chauhan, D.; Anderson, K. C. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007, 109, 1669-1677.
22. Neri, A.; Marmiroli, S.; Tassone, P.; Lombardi, L.; Nobili, L.; Verdelli, D.; Civallero, M.; Cosenza, M.; Bertacchini, J.; Federico, M.; De Pol, A.; Deliliers, G. L.; Sacchi, S. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signaling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk. Lymphoma 2008, 49, 1374-1383.
23. Raab, M. S.; Breitkreutz, I., Tonon, G.; Zhang, J.; Hayden, P. J.; Nguyen, T.; Fruehauf, J. H.; Lin, B. K.; Chauhan, D.; Hideshima, T.; Munshi, N. C.; Anderson, K. C.; Podar, K. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009, 113, 1513-1521.
24. Verdelli, D.; Nobili, L.; Todoerti, K.; Intini, D.; Cosenza, M.; Civallero, M.; Bertacchini, J.; Deliliers, G. L.; Sacchi, S.; Lombardi, L.; Neri, A. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. Hematol. Oncol., 2009, 27, 23-30.
25. Carducci, M. A.; Musib, L.; Kies, M. S.; Pili, R.; Truong, M.; Brahmer, J. R.; Cole, P.; Sullivan, R.; Riddle, J.; Schmidt, J.; Enas, N.; Sinha, V.; Thornton, D. E.; Herbst, R. S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 2006, 24, 4092-4099.
26. Ghobrial, I. M.; Munshi, N. C.; Harris, B. N.; Shi, P.; Porter, N. M.; Schlossman, R. L.; Laubach, J. P.; Anderson, K. C.; Desaiah, D.; Myrand, S. P.; Wooldridge, J. E.; Richardson, P. G.; Abonour, R. A Phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am. J. Hematol. 2011, 86, 573-578.
27. Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N. C.; Chauhan, D.; Richardson, P. G.; Anderson, K. C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107, 4053-4062.
28. Gajate, C.; Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007, 109, 711-719.
29. David, E.; Sinha, R.; Chen, J.; Sun, S. Y.; Kaufman, J. L.; Lonial, S. Perifosine synergistically enhances trail-induced myeloma cell apoptosis via up-regulation of death receptors. Clin. Cancer Res. 2008, 14, 5090-5098.
30. Huston, A.; Leleu, X.; Jia, X.; Moreau, A. S.; Ngo, H. T.; Runnels, J.; Anderson, J.; Alsayed, Y.; Roccaro, A.; Vallet, S.; Hatjiharissi, E.; Tai, Y. T.; Sportelli, P.; Munshi, N.; Richardson, P.; Hideshima, T.; Roodman, D. G.; Anderson, K. C.; Ghobrial, I. M. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin. Cancer Res. 2008, 14, 865-874.
31. Richardson, P. G.; Wolf, J.; Jakubowiak, A.; Zonder, J.; Lonial, S.; Irwin, D.; Densmore, J.; Krishnan, A.; Raje, N.; Bar, M.; Martin, T.; Schlossman, R.; Ghobrial, I. M.; Munshi, N.; Laubach, J.; Allerton, J.; Hideshima, T.; Colson, K.; Poradosu, E.; Gardner, L.; Sportelli, P.; Anderson, K. C. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J. Clin. Oncol. 2011, 29, 4243-4249.
32. Richardson, P. G.; Eng, C.; Kolesar, J.; Hideshima, T.; Anderson, K. C. Perifosine, an oral anticancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin. Drug. Metab. Toxicol. 2012, 8, 623-633.
33. Meng, H.; Yang, C.; Jin, J. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Leuk. Lymphoma 2008, 49, 1954-1962.
34. Dazert, E.; Hall, M. N. MTOR signaling in disease. Curr. Opin. Cell. Biol. 2011, 23, 744-755.
35. Shi, Y.; Gera, J.; Hu, L.; Hsu, J. H.; Bookstein, R.; Li, W.; Lichtenstein, A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res. 2002, 62, 5027-5034.
36. Frost, P.; Moatamed, F.; Hoang, B.; Shi, Y.; Gera, J.; Yan, H.; Frost, P.; Gibbons, J.; Lichtenstein, A. In vivo antitumor effect of mTOR inhibitor CCI-779 against multiple myeloma cells in a xenograft model. Blood 2004, 104, 4181-4187.
37. Farag, S. S.; Zhang, S.; Jansak, B. S.; Wang, X.; Kraut, E.; Chan, K.; Dancey, J. E.; Grever, M. R. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk. Res. 2009, 33, 1475-1480.
38. Ghobrial, I. M.; Weller, E.; Vij, R.; Munshi, N. C.; Banwait, R.; Bagshaw, M.; Schlossman, R.; Leduc, R.; Chuma, S.; Kunsman, J.; Laubach, J.; Jakubowiak, A. J.; Maiso, P.; Roccaro, A.; Armand, P.; Dollard, A.; Warren, D.; Harris, B.; Poon, T.; Sam A.; Rodig, S.; Anderson, K. C.; Richardson, P. G. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open label, dose-escalation study. Lancet Oncol. 2011, 12, 263-272.
39. Hofmeister, C. C.; Yang, X.; Pichiorri, F.; Chen, P.; Rozewski, D. M.; Johnson, A. J.; Lee, S.; Liu, Z.; Garr, C. L.; Hade, E. M.; Ji, J.; Schaaf, L. J.; Benson, D. M. Jr.; Kraut, E. H.; Hicks, W. J.; Chan, K. K.; Chen, C. S.; Farag, S. S.; Grever, M. R.; Byrd, J. C.; Phelps, M. A. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J. Clin. Oncol. 2011, 29, 3427-3424.
40. Raje N.; Kumar, S.; Hideshima, T.; Ishitsuka, K.; Chauhan, D.; Mitsiades, C.; Podar, K.; Le Gouill, S.; Richardson, P.; Munshi, N. C.; Stirling, D. I.; Antin, J. H.; Anderson, K. C. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004, 104, 4188-4193.
41. Andrews, P. D.; Knatko, E.; Moore, W. J.; Swedlow, J. R. Mitotic mechanics: the auroras come into view. Curr. Opin. Cell. Biol. 2003, 15, 672-683.
42. Santo, L.; Hideshima, T.; Cirstea, D.; Bandi, M.; Nelson, E. A.; Gorgun, G.; Rodig, S.; Vallet, S.; Pozzi, S.; Patel, K.; Unitt, C.; Squires, M.; Hu, Y.; Chauhan, D.; Mahindra, A.; Munshi, N. C.; Anderson, K. C.; Raje, N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin. Cancer. Res., 2011, 17, 3259-3271.
43. Shi, Y.; Reiman, T.; Li, W.; Maxwell, C.A.; Sen, S.; Pilarski, L.; Daniels, T. R.; Penichet, M. L.; Feldman, R.; Lichtenstein, A. Targeting aurora kinases as therapy in multiple myeloma Blood 2007, 109, 3915-3921.
44. Hose, D.; Rème, T.; Meissner, T.; Moreaux, J.; Seckinger, A.; Lewis, J.; Benes, V.; Benner, A.; Hundemer, M.; Hielscher, T.; Shaughnessy, J. D. Jr.; Barlogie, B.; Neben, K.; Krämer, A.; Hillengass, J.; Bertsch, U.; Jauch, A.; De Vos, J.; Rossi, J. F.; Möhler, T.; Blake, J.; Zimmermann, J.; Klein, B.; Goldschmidt, H. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 2009, 113, 4331-4340.
45. Tarte, K.; De Vos, J.; Thykjaer, T.; Zhan, F.; Fiol, G.; Costes, V.; Rème, T.; Legouffe, E.; Rossi, J. F.; Shaughnessy, J. Jr.; Ørntoft, T. F.; Klein, B. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002, 100, 1113-1122.
46. Görgün, G.; Calabrese, E.; Hideshima, T.; Ecsedy, J.; Perrone, G.; Mani, M.; Ikeda, H.; Bianchi, G.; Hu, Y.; Cirstea, D.; Santo, L.; Tai, Y. T.; Nahar, S.; Zheng, M.; Bandi, M.; Carrasco, R. D.; Raje, N.; Munshi, N.; Richardson, P.; Anderson, K. C. A novel Aurora A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010, 115, 5202-5213.
47. McCubrey, J. A.; Steelman, L. S.; Chappell, W. H.; Abrams, S. L.; Wong, E. W.; Chang, F.; Lehmann, B.; Terrian, D. M.; Milella, M.; Tafuri, A.; Stivala, F.; Libra, M.; Basecke, J.; Evangelisti, C.; Martelli, A. M.; Franklin, R.A. Roles of the RAF/MEK/ERK transformation pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773, 1263-1284.
48. Ogawa, M.; Nishiura, T.; Oritani, K.; Yoshida, H.; Yoshimura, M.; Okajima, Y.; Ishikawa, J.; Hashimoto, K.; Matsumura, I.; Tomiyama, Y.; Matsuzawa, Y. Cytokines prevent dexamethasoneinduced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res. 2000, 60, 4262-4269.
49. Podar, K.; Tai, Y. T.; Davies, F. E.; Lentzsch, S.; Sattler, M.; Hideshima, T.; Lin, B. K.; Gupta, D.; Shima, Y.; Chauhan, D.; Mitsiades, C.; Raje, N.; Richardson, P.; Anderson, K. C. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001, 98, 428-435.
50. Tai, Y. T.; Li, X. F.; Kreitkreutz, I.; Song, W.; Neri, P.; Catley, L.; Podar, K.; Hideshima, T.; Chauhan, D.; Raje, N.; Schlossman, R.; Richardson, P.; Munshi, N. C.; Anderson, K. C. Role of B-cellactivating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006, 66, 6675-6682.
51. Kim, K.; Kong, S.Y.; Fulciniti, M.; Li, X.; Song, W.; Nahar, S.; Burger, P.; Rumizen, M. J.; Podar, K.; Chauhan, D.; Hideshima, T.; Munshi, N. C.; Richardson, P.; Clark, A.; Ogden, J.; Goutopoulos, A.; Rastelli, L.; Anderson, K. C.; Tai, Y. T. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol. 2010, 149, 537-549.
52. Tai, Y. T.; Fulciniti, M.; Hideshima, T.; Song, W.; Leiba, M.; Li, X. F.; Rumizen, M.; Burger, P.; Morrison, A.; Podar, K.; Chauhan, D.; Tassone, P.; Richardson, P.; Munshi, N. C.; Ghobrial, I. M.; Anderson, K. C. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 2007, 110, 1656-1663.
53. Smith, E. M.; Boyd, K.; Davies, F. E. The potential role of epigenetic therapy in multiple myeloma. Br. J. Haematol. 2009, 148, 702-713.
54. Wolf, J. L.; Siegel, D.; Goldschmidt, H.; Hazell, K.; Bourquelot, P. M.; Bengoudifa, B. R.; Matous, J.; Vij, R.; de Magalhaes-Silverman, M.; Abonour, R.; Anderson, K. C.; Lonial, S. Phase II trial of the pan-deacetylase inhibitor panobinostat as single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma. 2012, [epub ahead of print].
55. Offidani, M.; Polloni, C.; Cavallo, F.; Marina Liberati, A.; Ballanti, S.; Pulini, S.; Catarini, M.; Alesiani, F.; Corvatta, L.; Gentili, S.; Caraffa, P.; Boccadoro, M.; Leoni, P.; Palumbo, A. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk. Lymphoma 2012, [epub ahead of print].
56. Tassone, P.; Tagliaferri, P.; Rossi, M.; Calimeri, T.; Bulotta, A.; Abbruzzese, A.; Caraglia, M.; Neri, P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr. Cancer Drug Targets 2009, 9, 854-870.
57. Henry, D. H.; Costa, L.; Goldwasser, F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti, G. V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; von Moos, R.; Willenbacher, W.; Woll, P. J.; Wang, J.; Jiang, Q.; Jun, S.; Dansey, R.; Yeh, H. Randomized, double blind study of Denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 2011, 29, 1125-1132.
58. Hughes, D. E.; Wright, K. R.; Uy, H. L.; Sasaki, A.; Yoneda, T.; Roodman, G. D.; Mundy, G. R.; Boyce, B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 1995, 10, 1478-1487.
59. Shipman, C. M.; Rogers, M. J.; Apperley, J. F.; Russell, R. G.; Croucher, P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 1997, 98, 665-672.
60. Aparicio, A.; Gardner, A.; Tu, Y.; Savage, A.; Berenson, J.; Lichtenstein, A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12, 220-229.
61. Schafer, W. R.; Rine, J. Protein prenylation: genes, enzymes, targets, and functions. Annu. Rev. Genet. 1992, 26, 209-237.
62. Hancock, J. F.; Magee, A. I.; Childs, J. E.; Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57,1167-1177.
63. Aznar, S.; Lacal, J. C. Rho signals to cell growth and apoptosis. Cancer Lett. 2001, 165, 1-10.
64. Caraglia, M.; Marra, M.; Leonetti, C.; Meo, G.; D'Alessandro, A. M.; Baldi, A.; Santini, D.; Tonini, G.; Bertieri, R.; Zupi, G.; Budillon, A.; Abbruzzese, A. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J. Cell. Physiol. 2007, 211, 533-543.
65. Caraglia, M.; D'Alessandro, A. M.; Marra, M.; Giuberti, G.; Vitale, G.; Viscomi, C.; Colao, A.; Prete, S. D.; Tagliaferri, P.; Tassone, P.; Budillon, A.; Venuta, S.; Abbruzzese, A. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004, 23, 6900-6913.
66. Tassone, P.; Forciniti, S.; Galea, E.; Morrone, G.; Turco, M. C.; Martinelli, V.; Tagliaferri, P.; Venuta, S. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14, 841-844.
67. Marra, M.; Abbruzzese, A.; Addeo, R.; Del Prete, S.; Tassone, P.; Tonini, G.; Tagliaferri, P.; Santini, D.; Caraglia, M. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr. Cancer Drug Targets 2009, 9, 791-800.
68. Caraglia, M.; Marra, M.; Naviglio, S.; Botti, G.; Addeo, R.; Abbruzzese, A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin. Pharmacother. 2010, 11, 141-154.
69. Morgan, G. J.; Davies, F. E.; Gregory, W. M.; Cocks, K.; Bell, S. E.; Szubert, A. J.; Navarro-Coy, N.; Drayson, M. T.; Owen, R. G.; Feyler, S.; Ashcroft, A. J.; Ross, F.; Byrne, J.; Roddie, H.; Rudin, C.; Cook, G.; Jackson, G. H.; Child, J. A.; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376, 1989-1999.
70. Mackay, F.; Browning, J. L. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol. 2002, 2, 465-475.
71. Neri, P.; Kumar, S.; Fulciniti, M. T.; Vallet, S.; Chhetri, S.; Mukherjee, S.; Tai, Y.; Chauhan, D.; Tassone, P.; Venuta, S.; Munshi, N. C.; Hideshima, T.; Anderson, K. C.; Raje, N. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 2007, 13, 5093-5099.
72. Vallet, S.; Raje, N.; Ishitsuka, K.; Hideshima, T.; Podar, K.; Chhetri, S.; Pozzi, S.; Breitkreutz, I.; Kiziltepe, T.; Yasui, H.; Ocio, E. M.; Shiraishi, N.; Jin, J.; Okawa, Y.; Ikeda, H.; Mukherjee, S.; Vaghela, N.; Cirstea, D.; Ladetto, M.; Boccadoro, M.; Anderson, K. C. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007, 110, 3744-3752.
73. Kaiser, M.; Mieth.; Liebisch, P.; Oberländer, R.; Rademacher, J.; Jakob, C.; Kleeberg, L.; Fleissner, C.; Braendle, E.; Peters, M.; Stover, D.; Sezer, O.; Heider U. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur. J. Hematol. 2008, 80, 490-494.
74. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S.A.; Shen, Z.; Patel, N.; Tai, Y.T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K. C.; Stover, D. R.; Munshi, N. C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114, 371-379.
75. Vallet, S.; Mukherjee, S.; Vaghela, N.; Hideshima, T.; Fulciniti, M.; Pozzi, S.; Santo, L.; Cirstea, D.; Patel, K.; Sohani, A. R.; Guimaraes, A.; Xie, W.; Chauhan, D.; Schoonmaker, J. A.; Attar, E.; Churchill, M.; Weller, E.; Munshi, N.; Seehra, J. S.; Weissleder, R.; Anderson, K. C.; Scadden, D. T.; Raje, N. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl. Acad. Sci. USA 2010, 107, 5124-5129.
76. Calimeri, T.; Battista, E.; Conforti, F.; Neri, P.; Di Martino, M. T.; Rossi, M.; Foresta, U.; Piro, E.; Ferrara, F.; Amorosi, A.; Bahlis, N.; Anderson, K. C.; Munshi, N.; Tagliaferri, P.; Causa, F.; Tassone, P. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia, 2011, 25, 707-711.
77. De Weerdt, S. Towards a myelma mouse. Nature, 2011, 480, S38-S39.